Novel Approach

Imetelstat inhibits the activity of the enzyme telomerase, a key target for anti-cancer therapeutics.
Learn more


Imetelstat in Patients with Multiple Myeloma

Helpful Information

  • Cytoreductive therapy is a treatment to reduce the size of a cancer tumor. This may also be referred to as "debulking." Surgery and chemotherapy are common cytoreductive therapies.
  • A relapse is when cancer returns after a period of improvement.
  • The response rate is the percentage of patients whose cancer decreases or disappears after treatment.
  • Maintenance therapy is treatment given to help prevent cancer from coming back after it has decreased or disappeared following the initial therapy.

This study is complete and closed to patient enrollment

A Phase 2 Trial to Determine the Effect of Imetelstat (GRN163L) on Patients With Previously Treated Multiple Myeloma

Geron enrolled patients in a clinical trial to determine the potential benefit of our product candidate, imetelstat, as a therapy for patients with multiple myeloma. This study enrolled patients who had been previously treated with cytoreductive therapy and whose cancer had stabilized or partially responded, but who still had detectable, non-progressing cancer and who were considered most likely to relapse.

In this Phase 2 clinical trial, our clinical researchers and investigators studied how imetelstat may affect the response rate of patients with previously treated multiple myeloma when given alone or in combination with lenalidomide maintenance therapy.

Additionally, we collected data on the change in myeloma cancer stem cells from the patient's bone marrow and circulation.

The preliminary data from this trial, as of July 30, 2012, have been published in an abstract in the journal, Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4898. The published data showed a rapid and significant decrease in myeloma progenitor cells that were detected in the blood over the course of imetelstat treatment in eight out of nine patients assessed. In addition, several patients experienced delayed, but sustained, clinical responses as measured by standard criteria. Four patients were discontinued from imetelstat therapy after receiving a median of seven doses of imetelstat. Of these four, two patients discontinued due to disease progression and two patients discontinued due to hematologic toxicity. Cytopenias, or reduced blood cell counts, were the most frequently reported toxicities with eight of ten patients demonstrating Grade 3-4 thrombocytopenia and neutropenia during cycle 2, which in many cases required dose reductions or holds in subsequent cycles.

Imetelstat is an investigational treatment for cancer and has not been approved by the FDA or any other regulatory agency.

To learn more about this clinical trial, please visit for the trial summary and enrollment criteria.

About Imetelstat

Imetelstat inhibits the activity of telomerase, which is an enzyme present in most types of cancer that enables tumor cells to replicate indefinitely. Development of imetelstat will continue under the Collaboration Agreement with Janssen Biotech, Inc. Click here for more information about the collaboration with Janssen. Learn more

Cancer Definitions

To learn more about the terms and definitions used in cancer clinical studies you may find the National Cancer Institute Dictionary of Cancer Terms a useful resource.

Para obtener más información acerca de los términos y las definiciones utilizadas en los estudios clínicos sobre el cáncer es posible que el Instituto Nacional del Cáncer Diccionario de cáncer en un recurso útil.

Additionally, patients or their physicians may directly contact the trial center for more information about how to participate. The study is currently being conducted in trial centers in the United States.

Novel Approach

Imetelstat inhibits the activity of the enzyme telomerase, a key target for anti-cancer therapeutics.
Learn more

Form content here please :)